<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">ACE2 is an ectoenzyme anchored to the plasma membrane of the cells of several tissues, especially those of the lower respiratory tract, heart, kidney and gastrointestinal tract [
 <xref rid="bib15" ref-type="bibr">15</xref>]. Inoculation of the 2019 nCoV onto surface layers of human airway epithelial cells 
 <italic>inÂ vitro</italic> causes cytopathic effects and cessation of the cilia movements [
 <xref rid="bib16" ref-type="bibr">16</xref>]. SARS-CoV highly replicates in the type I and II pneumocytes and in enterocytes, and the SARS-induced down-regulation of ACE2 receptors in lung epithelium contributes to the pathogenesis of acute lung injury and subsequent ARDS [
 <xref rid="bib15" ref-type="bibr">15</xref>,
 <xref rid="bib17" ref-type="bibr">17</xref>]. Whether the higher receptor affinity for ACE2 of SARS-CoV-2 than SARS-CoV could lead to a more severe lung involvement in COVID-19 than in SARS requires further investigation.
</p>
